Does Semax affect sleep?
Semax can affect sleep, and whether the effect is beneficial or disruptive largely depends on the dosage, time of administration, individual neurobiology, and the cause of any sleep problems.
No published study has used objective sleep measurement tools—such as polysomnography, a technique that tracks brain waves, eye movements, and muscle activity throughout the night—to directly measure the effects of Semax on sleep stages and architecture. Instead, studies provide indirect evidence. Documented effects of Semax on serotonin activity, BDNF levels, stress hormone regulation, and brain network activity involve systems closely intertwined with sleep regulation.
The most significant indirect evidence comes from studies showing that Semax increases serotonin turnover—enhancing its production, release, and breakdown—in the striatum [1] and elicits anti-anxiety and antidepressant effects with chronic use [2]. Both of these effects generally support rather than disrupt sleep quality. Serotonin is the direct chemical precursor to melatonin, the hormone that regulates the sleep-wake cycle, and increasing serotonergic activity in specific brain circuits is the same mechanism by which many antidepressant medications improve sleep in individuals with depression-related insomnia.
Semax's suppression of the HPA axis—including the reduction of stress-induced corticosterone and the prevention of adrenal hypertrophy under chronic stress [3]—theoretically also supports better sleep. Elevated cortisol and chronic overactivation of the stress system are among the most common biological causes of poor sleep quality.
Does Semax cause insomnia?
Insomnia is not listed as a side effect in any published clinical studies of Semax or animal studies. However, anecdotal user reports suggest that taking Semax too late in the day may make it difficult for some individuals to fall asleep.
This is not surprising, given the documented activating effects of Semax on brain networks. A resting-state functional MRI brain imaging study showed measurable changes in default mode network activity after only 5 minutes of Semax administration in healthy volunteers [4]. Stimulation of dopaminergic circuits and increased synaptic excitability [5] are features associated with mental activation, not sedation. A compound that sharpens concentration, increases neuronal activity, and enhances dopaminergic responses would logically disrupt sleep if taken close to bedtime, even if it doesn't cause insomnia through a direct pharmacological mechanism.
A chronobiological study of Semax—a study of its effects on biological rhythms—showed that chronic administration of Semax normalized the circadian rhythm of motor activity in rats. Semax increased the amplitude of this rhythm and resulted in beneficial effects of synchronizing biological rhythms [6]. This rhythm-regulating effect suggests that, at appropriate doses and times of administration, Semax may support the stability of circadian rhythm rather than disrupt it.
The same research group discovered that Semax had different effects on heart rate variability—an indicator of nervous system balance—depending on whether it was administered in the morning or evening. In the morning, it did not cause significant changes, while in the evening, it showed a beneficial effect decreasing sympathetic nervous system activity [7]. This dependence on the time of day indicates a broader biological sensitivity to timing, which likely extends to sleep-related effects.
Does Semax improve sleep or help with sleep disorders?
No published studies have directly investigated Semax as a treatment for insomnia or any specific sleep disorder. However, several documented mechanisms of Semax are relevant to sleep improvement, particularly in the context of poor sleep induced by stress or anxiety.
A study using a chronic unpredictable stress model showed that Semax reversed anhedonia, HPA axis hyperactivity, and reduced hippocampal BDNF levels [3]. These are the same biological disturbances underlying stress-related insomnia. The antistress effects of Semax may therefore indirectly improve sleep quality in individuals whose poor sleep is driven by chronic stress or anxiety. The reduction in anxiety-like behaviors documented in multiple animal models [2], [8] suggests that individuals taking Semax for its anxiolytic effects may experience an indirect improvement in sleep onset and maintenance.
It is important here to compare Semax and Selank. Selank, an anxiolytic related peptide often discussed alongside Semax, has a more sleep-compatible pharmacological profile. Its primary mechanism involves reducing anxiety by modulating GABA, the brain's main calming neurotransmitter, rather than the neuronal activation and cognitive enhancement characteristic of Semax. Users who experience sleep difficulties with Semax sometimes report that switching to Selank in the evening or carefully combining both peptides with appropriate timing better supports their sleep. However, this is based on anecdotal user experience rather than clinical research.
Does Semax affect deep sleep or REM sleep?
No published study has directly measured the effects of Semax on specific sleep stages—including slow-wave sleep (deep sleep) or rapid eye movement (REM) sleep—using polysomnographic methods. This represents a genuine gap in the scientific literature.
From the available data, it can be inferred that BDNF—which Semax significantly increases—plays an important role in the regulation of REM sleep and sleep-dependent memory consolidation. REM sleep is the stage of sleep during which the brain actively processes and consolidates memories from the day. Research outside the Semax literature has shown that BDNF promotes REM sleep and that the memory benefits of sleep are partially mediated by BDNF-TrkB signaling during sleep.
If the BDNF increase induced by Semax persists through sleep, it could theoretically enhance sleep-dependent memory processing—a beneficial rather than detrimental effect. However, this reasoning connects separate lines of evidence that have not been directly linked in a single study. It should be understood as a plausible hypothesis, rather than an established finding.
When is the best time to take Semax?
The best time to take Semax is generally in the morning or early afternoon, given its activating pharmacological profile, documented effects on mental alertness and neuronal excitability, and the day-time sensitivity observed in chronobiological studies. No controlled human studies have formally compared morning versus evening administration in terms of efficacy or sleep impact. This recommendation is based on pharmacological reasoning rather than direct comparative timing studies—however, it aligns with general principles for any alertness-enhancing compound.
Semax's activating properties — strengthening dopaminergic responses [9], improving glutamatergic synaptic activity [5], and extending frontal cortex activity observed in brain imaging [4] — make late administration logically problematic for individuals sensitive to evening stimulation.
The same properties make a morning dose of Semax well-suited to the goals most users have for it: improved focus, faster learning, better cognitive performance, and mental clarity throughout the workday.
Should Semax be taken before bed?
Taking Semax directly before bedtime is not recommended for most people due to its activating pharmacological profile.
The discovery that Semax had no effect on heart rate variability in the morning but had a significant effect in the evening [7] shows that the body's response to Semax is time-of-day dependent. The same dose elicits qualitatively different physiological effects depending on when it is administered. While the evening effect documented in this study was beneficial in terms of reducing sympathetic nervous system activity, Semax's broader activating effects on the brain—including increased calcium signaling in the hippocampus [10] and enhanced synaptic activity [5]—would likely oppose the quieting of brain activity needed for sleep onset.
However, it should be noted that individual variability is significant, and some users may not experience sleep disturbances with evening Semax use, especially at lower doses. Key variables appear to be dose size—higher doses are more likely to cause noticeable stimulation—and individual sensitivity to dopaminergic and serotonergic activation. Individuals who have difficulty winding down in the evening, are sensitive to caffeine in the afternoon, or have an anxious nervous system tendency should be particularly cautious about taking Semax within several hours of planned sleep.
Does the time of day affect Semax's effectiveness?
Yes — the time of day seems to affect how Semax works in the body, although this has only been directly studied in the context of cardiac chronobiology, not cognitive performance.
Arushanian and Popov's study clearly showed different heart rate variability responses to Semax depending on whether it was administered in the morning or evening [7]. A chronobiological study of the circadian rhythm demonstrated that chronic administration of Semax influenced the strength, timing, and spectral characteristics of the diurnal locomotor activity rhythm [6]. This indicates that Semax interacts with the body's internal timing systems, rather than simply producing the same effect regardless of the time of day.
From a practical standpoint, Semax's activating and nootropic effects are most useful and least likely to disrupt sleep when administration coincides with periods of intended cognitive activity. In clinical post-stroke rehabilitation protocols, Semax was administered during daily treatment courses without specific timing concerns reported in the literature [11], [12], which is consistent with daily use as standard clinical practice.
Should Semax be taken with food?
No published studies have specifically investigated whether food intake affects Semax's pharmacokinetics—how it is absorbed, distributed, and eliminated by the body—or its pharmacodynamic effects when administered intranasally.
Because the nasal route delivers the peptide directly to the brain via the olfactory pathway, Semax largely bypasses gastrointestinal processing entirely. It does not need to go through the stomach and intestines or undergo first-pass metabolism in the liver. This means that the presence or absence of food in the stomach should not significantly alter the amount of Semax reaching the brain or the speed of this process.
When administered subcutaneously, food intake also does not significantly affect the absorption of the peptide from subcutaneous tissue. Therefore, there is no strong pharmacological reason to link the timing of nasal or injected Semax administration with meals.
Do Semax and Selank together affect sleep?
Semax and Selank have complementary and partially opposing pharmacological profiles that, with thoughtful timing, may induce a more sleep-compatible effect than Semax used alone. However, no published study has directly investigated the effects of this combination on sleep quality, sleep architecture, or insomnia.
Selank is a synthetic heptapeptide developed as an analog of tuftsin, a naturally occurring peptide of the immune system. It was created concurrently with Semax at the same Russian Institute of Molecular Genetics. Its main pharmacological profile is anxiolytic — it reduces anxiety — through mechanisms including modulation of GABA receptors (increasing the brain's calming signals), inhibition of enkephalinase (prolonging the activity of the brain's own natural calming peptides called enkephalins), and modulation of pro-inflammatory cytokines [13].
Unlike Semax, which has a more activating and nootropic profile, Selank's main effect is calming and anxiolytic—without causing sedation or cognitive impairment. In a resting-state functional MRI study analyzing both peptides in the same participants, Selank and Semax elicited both common and distinct effects on functional connectivity between the right amygdala—the brain's main hub for fear and threat detection—and surrounding temporal cortex areas [14]. Selank demonstrated a pattern more consistent with emotional dampening.
Which is better for sleep - Semax or Selank?
If the goal is sleep improvement, Selank has a more directly sleep-compatible pharmacological profile than Semax and would generally be the better choice of these two peptides. Selank's anxiolytic and GABA-modulating properties directly address over-arousal and intrusive thoughts—some of the most common causes of difficulty falling asleep and staying asleep—without the neuronal activation and dopaminergic enhancement that can make Semax disruptive to sleep in the evening.
The enkephalinase inhibitory effect of Selank—which prolongs the activity of the brain's own enkephalins, molecules similar to endorphins that induce sedation and a mild mood elevation [13]—also contributes to its sedating effect, promoting the brain's readiness for sleep.
However, it is important to note that this comparison is based on pharmacological reasoning from separate studies of each peptide individually, rather than from any direct comparative study of their effects on sleep. Neither peptide has been formally evaluated as a sleep aid in controlled clinical trials, and recommending either specifically for sleep disorders goes beyond what current evidence justifies.
Does the combination of Semax and Selank affect sleep differently than each peptide individually?
The combination of Semax and Selank is often used in Russian clinical practice and discussed in nootropic communities as a way to balance the activating effects of Semax with the calming properties of Selank—potentially creating a more balanced cognitive and emotional effect than either compound used alone.
In the functional connectivity study, both peptides were investigated in the same 52 healthy participants, allowing for a direct comparison of their individual effects on amygdala-related functional connectivity. The results revealed both overlapping and distinct effects, suggesting that their combined use would not simply duplicate the effects of one peptide, but rather induce an additive combination of separate pharmacological actions [14]. Whether this combination specifically translates to improved sleep has not been investigated.
The theoretical basis for the beneficial impact of the combination on sleep in the evening is simple. If Selank is taken in the evening for anxiety reduction and to promote calmness, and Semax only in the morning for cognitive activation, both peptides are essentially acting sequentially rather than simultaneously. Semax supports daytime cognitive performance; Selank supports evening relaxation and sleep onset. This is a practical timing strategy that many users online describe—however, it must be clearly emphasized that this is a user-derived dosing practice, not a clinically validated protocol.
What's the best way to space out Semax and Selank if sleep is a problem?
Based on the pharmacological profiles of both peptides and available indirect evidence, the temporal approach described by many users—though no clinical trial has formally tested it—is to take Semax in the morning, to leverage its cognitive and activating properties throughout the workday, and to reserve Selank for the afternoon or evening, when its anxiolytic and calming effects are most useful for transitioning into sleep.
This approach utilizes the stimulating properties of Semax when they are most beneficial, and the calming properties of Selank neutralize any residual neuronal activation in the hours before sleep.
Functional connectivity studies analyzing both peptides were conducted with brain imaging measurements at baseline, 5 minutes, and 20 minutes post-administration [14], confirming that both peptides elicit rapid effects on the central nervous system. This implies that the timing of administration in relation to desired effects—and sleep—is of practical importance. Taking Semax several hours before sleep and Selank closer to evening or bedtime is an approach consistent with the pharmacological properties of each compound, even in the absence of a clinical trial specifically confirming the sleep benefits of this schedule.
Does the combination of Semax and Selank affect cortisol or the HPA axis?
Both Semax and Selank independently show evidence for suppressing the stress response and reducing HPA axis hyperactivity. This suggests that their combination may have complementary anti-stress effects relevant to cortisol dysregulation often implicated in sleep disturbances.
Semax reversed adrenal enlargement induced by chronic stress and lowered corticosterone levels in stressed rats [3], [15]. Selank reduced pro-inflammatory stress markers, including IL-1β, IL-6, and TNF-α, under social stress conditions [13], reflecting anti-stress and anti-inflammatory activity through a different yet compatible mechanism.
Elevated evening cortisol—sometimes informally described as being „tired but wired,” where a person feels physically exhausted but unable to switch off their thoughts—is one of the most common hormonal causes of difficulty falling asleep despite fatigue. Compounds that reduce HPA axis reactivity without completely suppressing it could theoretically help normalize the natural cortisol rhythm that supports healthy sleep.
However, it must be clearly stated that no study has directly measured cortisol or HPA axis markers in response to the Semax-Selank combination. The effects of combining both compounds on stress hormone regulation have not been directly investigated. The suggestion that this combination may beneficially affect sleep disturbances related to the HPA axis is based on separate evidence bases for the individual effects of each compound. This is a plausible hypothesis, but it requires direct investigation before it can be presented as an established finding.
Disclaimer
This article is for educational and informational/scientific purposes only and should not be interpreted as medical advice, diagnosis, treatment recommendation, or claim of safety or efficacy of Semax or Selank for any condition. Both Semax and Selank remain investigational compounds in most countries, including the United States and most European countries, and are not approved by the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. They are approved and used clinically in Russia and some Eastern European countries. Most of the evidence presented in this article comes from preclinical animal studies and a limited number of human clinical trials. Additional, well-designed clinical studies are necessary to more accurately establish the safety, efficacy, mechanisms of action, and long-term effects of Semax and Selank in humans.
References
Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[2] Vilenskiĭ, D. A., Levitskaia, N. G., Andreeva, L. A., Alfeeva, L. Yu., Kamenskiĭ, A. A., & Miasoedov, N. F. (2007). Effects of chronic Semax administration on exploratory activity and emotional reaction in white rats. Sechenov Physiological Journal of Russia, 93(6), 661–669. PMID: 17850024
[3] Inozemtseva, L. S., Yatsenko, K. A., Glazova, N. Yu., Kamensky, A. A., Myasoedov, N. F., Levitskaya, N. G., Grivennikov, I. A., & Dolotov, O. V. (2024). Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology, 984, 177068. https://doi.org/10.1016/j.ejphar.2024.177068
[4] Lebedeva, I. S., Panikratova, Ya. R., Sokolov, O. Yu., Kupriyanov, D. A., Rumshiskaya, A. D., Kost, N. V., & Myasoedov, N. F. (2018). Effects of Semax on the default mode network of the brain. Bulletin of Experimental Biology and Medicine, 165(5), 653–656. https://doi.org/10.1007/s10517-018-4234-3
[5] Shypshyna, M. S., Veselovsky, N. S., Myasoedov, N. F., Shram, S. I., & Fedulova, S. A. (2015). Effect of peptide Semax on synaptic activity and short-term plasticity of glutamatergic synapses of co-cultured dorsal root ganglion and dorsal horn neurons. Physiological Journal, 61(4), 48–55. https://doi.org/10.15407/fz61.04.048
[6] Arushanian, E. B., & Popov, A. V. (2008). Chronotropic activity of Semax. Experimental and Clinical Pharmacology, 71(2), 14–16. PMID: 18488900 https://europepmc.org/article/med/18488900
Arushanian, E. B., & Popov, A. V. (2009). Effect of semax on heart rate variability in various daytime periods. Experimental and Clinical Pharmacology, 72(2), 32–34. PMID: 19441725 https://pubmed.ncbi.nlm.nih.gov/19441725/
[8] Levitskaia, N. G., Sebentsova, E. A., Andreeva, L. A., Alfeeva, L. Yu., Kamenskiĭ, A. A., & Miasoedov, N. F. (2010). Influence of Semax on the emotional state of white rats in the norm and against the background of cholecystokinin-tetrapeptide action. News of the Academy of Sciences, Biological Series, (2), 231–237. PMID: 20387390
[9] Eremin, K. O., Saransaari, P., Oja, S., & Raevskiĭ, K. S. (2004). Semax potentiates effects of D-amphetamine on the level of extracellular dopamine in the Sprague-Dawley rat striatum and on the locomotor activity of C57BL/6 mice. Experimental and Clinical Pharmacology, 67(2), 8–11. PMID: 15188751
Kolbaev, S. N., Sharonova, I. N., & Skrebitsky, V. G. (2025). The effect of peptide Semax, an ACTH(4-10) analogue, on intracellular calcium dynamics in rat brain neurons. Bulletin of Experimental Biology and Medicine, 179(4), 416–420. https://doi.org/10.1007/s10517-025-06501-z
Gusev, E. I., Skvortsova, V. I., Miasoedov, N. F., Nezavibat’ko, V. N., Zhuravleva, E. Yu., & Vanichkin, A. V. (1997). Effectiveness of semax in acute period of hemispheric ischemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 97(6), 26–34. PMID: 11517472
[12] Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
[13] Yasenyavskaya, A. L., Samotrueva, M. A., Tsibizova, A. A., Bashkina, O. A., Myasoedov, N. F., & Andreeva, L. A. (2021). The influence of Selank on the level of cytokines under the conditions of „social” stress. Current Reviews in Clinical and Experimental Pharmacology, 16(2), 162-167. https://doi.org/10.2174/1574884715666200704152810
[14] Panikratova, Ya. R., Lebedeva, I. S., Sokolov, O. Yu., Rumshiskaya, A. D., Kupriyanov, D. A., Kost, N. V., & Myasoedov, N. F. (2020). Functional connectomic approach to studying Selank and Semax effects. Doklady Biological Sciences, 490(1), 9–11. https://doi.org/10.1134/S001249662001007X
[15] Svishcheva, M. V., Mishina, Ye. S., Medvedeva, O. A., Bobyntsev, I. I., Mukhina, A. Yu., Kalutskii, P. V., Andreeva, L. A., & Myasoedov, N. F. (2021). Morphofunctional state of the large intestine in rats under conditions of restraint stress and administration of peptide ACTH(4-7)-PGP (Semax). Bulletin of Experimental Biology and Medicine, 170(3), 384–388. https://doi.org/10.1007/s10517-021-05072-z